RhoB抑制慢性粒细胞白血病细胞的生长-东南大学学报医学版

RhoB抑制慢性粒细胞白血病细胞的生长

单位：1. 苏州大学唐仲英血液学研究中心,江苏苏州 215123;
2. 苏州大学附属第一医院血液科,江苏苏州 215006

分类号：R733.72; Q253

出版年·卷·期（页码）：2012·31·第五期（537-542）

摘要：

目的:研究RhoB对慢性粒细胞白血病(chronic myeloid leukemia,CML)细胞增殖能力的影响。方法:用PCR扩增RhoB编码区并构建几种RhoB脂类修饰突变体。以慢病毒为载体携带RhoB及其突变体在CML细胞中过表达后,检测细胞增殖能力,并分析细胞的周期进程。结果:过表达RhoB能抑制MEG-01细胞及CML患者CD34⁺细胞的增殖;脂类修饰缺失的RhoBC193G不能抑制CML细胞的增殖;单独进行法尼基(F)修饰和单独进行牻牛儿基牻牛儿基(GG)修饰的RhoB均可抑制CML细胞的增殖;过表达RhoB及其单种脂类修饰变体将CML细胞阻滞于G₂/M期。结论:RhoB需要F或GG类型的脂类修饰才能抑制CML细胞的生长并将CML细胞阻滞于G₂/M期。

Objective: To study the effects of RhoB on the proliferation of chronic myeloid leukemia(CML) cells. Methods: Wild type RhoB and its lipid modification variants were amplified by PCR; lentiviral vectors were constructed to overexpress RhoB and its variants in CML cells; effect on the growth of CML cell and the alteration of cell cycle were analyzed. Results: Overexpression of RhoB in MEG-01 and CD34⁺ cells from CML patients reduced their proliferation. The lipid modification deficient variant RhoBC193G could not inhibit the growth of CML cells. Both farnesylated(F) and geranylgeranylated(GG) RhoB(RhoB-F and RhoB-GG) decreased the proliferation ability of CML cells. RhoB, RhoB-F and RhoB-GG transduced CML cells resided more at G₂/M phase compared with control or RhoBC193G transducted cells. Conclusion: RhoB required lipid modification to suppress the growth of CML cells, which is correlated with the arrest of cells at G₂/M.

参考文献：

[1] SHERBENOU D W,DRUKER B J.Applying the discovery of the Philadelphia chromosome[J].J Clin Invest,2007,117:2067-2074.
[2] MULLOY J C,CANCELAS J A,FILIPPI M D,et al.Rho GTPases in hematopoiesis and hemopathies[J].Blood,2010,115:936-947.
[3] PRENDERGAST G C.Actin’ up:RhoB in cancer and apoptosis[J].Nat Rev Cancer,2001,1:162-168.
[4] HUANG M,PRENDERGAST G C.RhoB in cancer suppression[J].Histol Histopathol,2006,21:213-218.
[5] CHEN Z,SUN J,PRADINES A,et al.Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice[J].J Biol Chem,2000,275:17974-17978.
[6] 吴平平,苏昀,金治,等.RhoA蛋白通路在DLC-1基因调控人结肠癌HT29细胞周期中的作用及其机制[J].东南大学学报:医学版,28(4):247-251.
[7] 曹倪豪,陈明.BTG1在肾透明细胞癌组织中的表达及对786-O细胞株增殖和凋亡的影响[J].东南大学学报:医学版,2011,30(4):583-587.
[8] VOLANIS D,ZARAVINOS A,KADIYSKA T,et al.Expression profile of Rho kinases in urinary bladder cancer[J].J BUON,2011,16:511-521.
[9] MAZIERES J,ANTONIA T,DASTE G,et al.Loss of RhoB expression in human lung cancer progression[J].Clin Cancer Res,2004,10:2742-2750.
[10] LIU A X,RANE N,LIU J P,et al.RhoB is dispensable for mouse development,but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells[J].Mol Cell Biol,2001,21:6906-6912.
[11] COUDERC B,PRADINES A,RAFII A,et al.In vivo restoration of RhoB expression leads to ovarian tumor regression[J].Cancer Gene Ther,2008,15:456-464.
[12] ZALCMAN G,CLOSSON V,LINARES-CRUZ G,et al.Regulation of Ras-related RhoB protein expression during the cell cycle[J].Oncogene,1995,10:1935-1945.
[13] WHERLOCK M,GAMPEL A,FUTTER C,et al.Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase[J].J Cell Sci,2004,117:3221-3231.
[14] MAZIERES J,TILLEMENT V,ALLAL C,et al.Geranylgeranylated,but not farnesylated,RhoB suppresses Ras transformation of NIH-3T3 cells[J].Exp Cell Res,2005,304:354-364.
[15] ADINI I,RABINOVITZ I,SUN J F,et al.RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development[J].Genes Dev,2003,17:2721-2732.
[16] MILIA J,TEYSSIER F,DALENC F,et al.Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication[J].Cell Death Differ,2005,12:492-501.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录